InterVenn welcomes Andrew Quong, PhD, as CEO!
November 7, 2022
A novel, highly accurate liquid biopsy-based glycoproteomic predictor of checkpoint inhibitor treatment benefit in advanced non-small cell lung cancer

Get in touch